Menu
Search
|

Menu

Close
X

Tigenix NV TIG.OQ (NASDAQ Stock Exchange Global Select Market)

41.75 USD
-- (--)
As of Feb 21
chart
Previous Close 41.75
Open --
Volume --
3m Avg Volume 3,558
Today’s High --
Today’s Low --
52 Week High 43.94
52 Week Low 14.32
Shares Outstanding (mil) 266.49
Market Capitalization (mil) 282.48
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.20 Mean rating from 5 analysts

KEY STATS

Revenue (mm, EUR)
FY17
0
FY16
25
FY15
2
EPS (EUR)
FY17
-0.100
FY16
0.012
FY15
-0.211
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
11.25
5.77
Price to Book (MRQ)
vs sector
5.08
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
66.41
16.52
LT Debt to Equity (MRQ)
vs sector
8.23
12.22
Return on Investment (TTM)
vs sector
-18.81
14.43
Return on Equity (TTM)
vs sector
-32.21
16.13

EXECUTIVE LEADERSHIP

Jean Stephenne
Independent Chairman of the Board, representing Innoste SA, Since 2012
Salary: --
Bonus: --
Eduardo Bravo Fernandez de Araoz
Chief Executive Officer, Managing Director, Executive Director, Since 2011
Salary: --
Bonus: --
Claudia D'Augusta
Chief Financial Officer, Chief Compliance Officer, Company Secretary, Since 2011
Salary: --
Bonus: --
Wilfried Dalemans
Chief Technology Officer, Since
Salary: --
Bonus: --
Gil Beyen
Chief Business Officer, Managing Director, Executive Director, representing of Gil Beyen BVBA, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Box 2, Romeinse Straat 12
HEVERLEE     3001

Phone: +3216.396060

TiGenix NV is a Belgium-based biopharmaceutical company focused on the development and commercialization of therapeutics from its platforms of allogeneic, or donor-derived, expanded stem cells. The Company's two products from the adipose-derived stem cell platform are in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn’s disease patients, and Cx611 which has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. From the Company's cardiac stem cell-based platform are AlloCSC-01 with a Phase II clinical trial in Acute Myocardial Infarction, and AlloCSC-02 being developed for a chronic indication. TiGenix NV operates in the domestic market and in Madrid, Spain.

SPONSORED STORIES